The current standard of care (SoC) for glioblastoma and high-risk IDH-mutant gliomas, established by the landmark Stupp article, combines maximal safe surgical resection with concurrent radiotherapy and temozolomide (TMZ) chemotherapy, followed by adjuvant TMZ maintenance therapy [1,5,6]. This evidence concerns the gene IDH1 and glioma.